Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Pociredir in Sickle Cell Disease
NCT07431398Phase 1Terminated
- Sponsor
- Fulcrum Therapeutics
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pociredir in sickle cell disease (SCD) (2 cohorts), sponsored by Fulcrum Therapeutics. Primary endpoints: Plasma concentration of pociredir, Maximum plasma concentration and 8 more. Started Dec 2025; status: terminated.
02
Drugs
pociredir
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07431398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431398.